Rate My Professor John Haynes

Haynes has led or co-led multiple research projects, notably NHMRC-funded "Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease" (2015-2018), "Use of hESC-derived models to identify new therapeutic targets for treatment of neurodegenerative diseases" (2018-2019), and others on Alport syndrome and neurogenesis. With 89 peer-reviewed articles among 106 research outputs, standout publications include "TGFβ3, dibutyryl cAMP and a notch inhibitor modulate phenotype late in stem cell-derived dopaminergic neuron maturation" (2023, Frontiers in Cell and Developmental Biology), "Nuclear Transporter IPO13 Is Central to Efficient Neuronal Differentiation" (2022, Cells), "Chronic stress and Alzheimer’s disease: the interplay between the hypothalamic–pituitary–adrenal axis, genetics and microglia" (2021, Biological Reviews), and "Compartmentalized microfluidic chambers enable long-term maintenance and communication between human pluripotent stem cell-derived forebrain and midbrain neurons" (2021, Lab on a Chip). He delivers lectures on renal physiology, pharmacology, second messenger signalling, and neurodegeneration in the Bachelor of Pharmaceutical Sciences and Bachelor of Pharmacy programs and supervises PhD students in neurodegeneration research.